Elevating Dermatology Prior Authorization with Da Vinci PAS

The Unique Prior Authorization Challenges in Dermatology

Dermatology prior authorizations are often triggered by high-cost specialty medications, particularly biologics for chronic conditions like psoriasis, psoriatic arthritis, and atopic dermatitis. Procedures such as Mohs micrographic surgery also frequently require PA. Practices contend with complex step therapy protocols, periodic re-authorization cycles, and the need for detailed clinical documentation, including disease severity scores and trial-and-failure histories, making manual processes inefficient and prone to errors.

Common Dermatology Prior Authorization Triggers and Documentation Requirements

• Biologics for psoriasis and psoriatic arthritis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi), requiring documentation of PASI/BSA scores, prior topical/phototherapy trials, and conventional systemic therapy history.
• Biologics for atopic dermatitis (e.g., Dupixent, Adbry), necessitating EASI/SCORAD severity documentation and prior topical therapy trials.
• Hidradenitis suppurativa biologics (e.g., adalimumab), with specific diagnostic and treatment history requirements.
• Mohs micrographic surgery, which often requires conformance with AAD Appropriate Use Criteria based on tumor type and site.
• Advanced skin cancer treatments and phototherapy, where PA is triggered by specific drug regimens or home phototherapy prescriptions.

Transforming Dermatology Prior Authorization with Da Vinci PAS

The HL7 Da Vinci Prior Authorization Support (PAS) implementation guide, built on FHIR R4, standardizes the electronic exchange of prior authorization requests and responses. For dermatology, this means moving beyond unstructured attachments and manual portal entries to a system where clinical data, such as PASI scores or Mohs AUC criteria, can be submitted as structured FHIR resources. This shift enables payers to conduct more efficient, potentially automated, reviews, reducing turnaround times and improving decision consistency.

Klivira's Da Vinci PAS Workflow for Dermatology Practices

Klivira integrates Da Vinci PAS into the dermatology clinical workflow, starting with Coverage Requirements Discovery (CRD) at the point of order entry to proactively identify PA needs. Documentation Templates and Rules (DTR) guide the assembly of necessary clinical evidence, populating structured FHIR resources directly from the EMR. The completed PAS request, including detailed documentation for biologics or Mohs surgery, is then submitted via the standardized FHIR $submit operation, ensuring a consistent and auditable process.

Addressing Common Dermatology PA Denials with Structured Data

Many dermatology PA denials stem from missing documentation, such as inadequate proof of step therapy compliance for psoriasis biologics or a mismatch with Mohs AUC. By using Da Vinci PAS, Klivira facilitates the submission of structured clinical data, directly addressing these common denial reasons. This includes ensuring all required pre-biologic screenings (e.g., TB, hepatitis) are documented and that disease severity (e.g., EASI/SCORAD) is clearly communicated, leading to more complete and accurate submissions.

Navigating Payer Conformance and CMS-0057-F

While Da Vinci PAS adoption is growing, particularly with the impetus from CMS-0057-F for impacted payers (Medicare Advantage, Medicaid managed-care, CHIP managed-care, QHP-on-FFM) to implement Prior Authorization APIs by 2027, not all payers are fully conformant today. Klivira's platform intelligently routes PA requests, leveraging Da Vinci PAS where available and seamlessly falling back to X12 278 or payer-specific portals for non-conformant payers, ensuring continuous coverage for dermatology services.